請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29197
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 余家利(Chia-Li Yu) | |
dc.contributor.author | Pei-Hsuan Lai | en |
dc.contributor.author | 賴佩璇 | zh_TW |
dc.date.accessioned | 2021-06-13T01:02:42Z | - |
dc.date.available | 2012-10-05 | |
dc.date.copyright | 2011-10-05 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-04 | |
dc.identifier.citation | Bunn, C.C., and Black, C.M. (1999). Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 117, 207-208.
Charkoudian, N. (2003). Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc 78, 603-612. Harris, S.L., and Levine, A.J. (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908. LeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger, T.A., Jr., Rowell, N., and Wollheim, F. (1988). Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15, 202-205. Mercie, P., Seigneur, M., and Conri, C. (1995). Plasma thrombomodulin as a marker of vascular damage in systemic sclerosis. J Rheumatol 22, 1440-1441. Mittag, M., Beckheinrich, P., and Haustein, U.F. (2001). Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 81, 294-297. Raynaud, M. (1862). Local Asphyxia and Symmetrical Gangrene of the Extremities. London: New Sydenham Society. . Reimer, G. (1990). Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 16, 169-183. Sadler, J.E. (1991). von Willebrand factor. J Biol Chem 266, 22777-22780. Ahmed, S.S., Tan, F.K., Arnett, F.C., Jin, L., and Geng, Y.J. (2006). Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 54, 2250-2262. Bakst, R., Merola, J.F., Franks, A.G., Jr., and Sanchez, M. (2008). Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol 59, 633-653. Bunn, C.C., and Black, C.M. (1999). Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 117, 207-208. Chotani, M.A., Flavahan, S., Mitra, S., Daunt, D., and Flavahan, N.A. (2000). Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278, H1075-1083. Diot, E., Giraudeau, B., Diot, P., Degenne, D., Ritz, L., Guilmot, J.L., and Lemarie, E. (1999). Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 116, 715-720. Earnshaw, W., Bordwell, B., Marino, C., and Rothfield, N. (1986). Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest 77, 426-430. Flavahan, N.A., Flavahan, S., Mitra, S., and Chotani, M.A. (2003). The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 29, 275-291, vi. Furspan, P.B., Chatterjee, S., and Freedman, R.R. (2004). Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 50, 1578-1585. Garcia-Carrasco, M., Jimenez-Hernandez, M., Escarcega, R.O., Mendoza-Pinto, C., Pardo-Santos, R., Levy, R., Maldonado, C.G., Chavez, G.P., and Cervera, R. (2008). Treatment of Raynaud's phenomenon. Autoimmun Rev 8, 62-68. Giordano, M., Valentini, G., Migliaresi, S., Picillo, U., and Vatti, M. (1986). Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 13, 911-916. Henault, J., Robitaille, G., Senecal, J.L., and Raymond, Y. (2006). DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54, 963-973. Henault, J., Tremblay, M., Clement, I., Raymond, Y., and Senecal, J.L. (2004). Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 50, 3265-3274. Hildebrandt, S., Weiner, E.S., Senecal, J.L., Noell, G.S., Earnshaw, W.C., and Rothfield, N.F. (1990). Autoantibodies to topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 57, 399-410. Hirschl, M., Hirschl, K., Lenz, M., Katzenschlager, R., Hutter, H.P., and Kundi, M. (2006). Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 54, 1974-1981. Ho, K.T., and Reveille, J.D. (2003). The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5, 80-93. Jimenez, S.A., and Derk, C.T. (2004). Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140, 37-50. Kahaleh, B., and Matucci-Cerinic, M. (1995). Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 38, 1-4. Kallenberg, C.G. (1990). Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am 16, 11-30. Kawaguchi, Y., Takagi, K., Hara, M., Fukasawa, C., Sugiura, T., Nishimagi, E., Harigai, M., and Kamatani, N. (2004). Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 50, 216-226. Kim, D., Peck, A., Santer, D., Patole, P., Schwartz, S.M., Molitor, J.A., Arnett, F.C., and Elkon, K.B. (2008). Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 58, 2163-2173. Leighton, C. (2001). Drug treatment of scleroderma. Drugs 61, 419-427. LeRoy, E.C. (1996). Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22, 675-694. LeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger, T.A., Jr., Rowell, N., and Wollheim, F. (1988). Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15, 202-205. LeRoy, E.C., and Medsger, T.A., Jr. (1992). Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 10, 485-488. LeRoy, E.C., and Medsger, T.A., Jr. (2001). Criteria for the classification of early systemic sclerosis. J Rheumatol 28, 1573-1576. Lewis., T. (1929). Experiments relating to the peripheral mechanisms involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud’s disease. Heart 15. Mitri, G.M., Lucas, M., Fertig, N., Steen, V.D., and Medsger, T.A., Jr. (2003). A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48, 203-209. Morelli, S., De Marzio, P., Valesini, G., and Bonavita, M.S. (1993). [Pulmonary hypertension and systemic sclerosis]. G Ital Cardiol 23, 871-876. Muro, Y., Matsumoto, Y., and Ohashi, M. (1992). Anticentromere-protein-B--DNA complex activities in anticentromere antibody-positive patients. Arch Dermatol Res 284, 396-399. Pistorius, M.A., Planchon, B., Schott, J.J., and Lemarec, H. (2006). [Heredity and genetic aspects of Raynaud's disease]. J Mal Vasc 31, 10-15. Rajagopalan, S., Pfenninger, D., Kehrer, C., Chakrabarti, A., Somers, E., Pavlic, R., Mukherjee, D., Brook, R., D'Alecy, L.G., and Kaplan, M.J. (2003). Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum 48, 1992-2000. Ramirez-Sandoval, R., Sanchez-Rodriguez, S.H., Herrera-van Oostdam, D., Avalos-Diaz, E., and Herrera-Esparza, R. (2003). Antinuclear antibodies recognize cellular autoantigens driven by apoptosis. Joint Bone Spine 70, 187-194. Raynaud, M. (1862). Local Asphyxia and Symmetrical Gangrene of the Extremities. London: New Sydenham Society. . Reimer, G. (1990). Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 16, 169-183. Reveille, J.D., and Solomon, D.H. (2003). Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49, 399-412. Robitaille, G., Henault, J., Christin, M.S., Senecal, J.L., and Raymond, Y. (2007). The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells. Arthritis Rheum 56, 3814-3826. Sakkas, L.I. (2005). New developments in the pathogenesis of systemic sclerosis. Autoimmunity 38, 113-116. Sapadin, A.N., and Fleischmajer, R. (2002). Treatment of scleroderma. Arch Dermatol 138, 99-105. Scussel-Lonzetti, L., Joyal, F., Raynauld, J.P., Roussin, A., Rich, E., Goulet, J.R., Raymond, Y., and Senecal, J.L. (2002). Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 81, 154-167. Servettaz, A., Agard, C., Tamby, M.C., Guilpain, P., Guillevin, L., and Mouthon, L. (2006). [Systemic sclerosis: pathophysiology of a multifaceted disease]. Presse Med 35, 1903-1915. Steen, V.D., Powell, D.L., and Medsger, T.A., Jr. (1988). Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31, 196-203. Tamby, M.C., Chanseaud, Y., Guillevin, L., and Mouthon, L. (2003). New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2, 152-157. Weiner, E.S., Earnshaw, W.C., Senecal, J.L., Bordwell, B., Johnson, P., and Rothfield, N.F. (1988). Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 31, 378-385. Weiner, E.S., Hildebrandt, S., Senecal, J.L., Daniels, L., Noell, S., Joyal, F., Roussin, A., Earnshaw, W., and Rothfield, N.F. (1991). Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 34, 68-77. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29197 | - |
dc.description.abstract | 全身性硬化症是一種系統性的自體免疫疾病,其特點包括過度活化的免疫反 應、血管損傷、發炎反應和皮膚及許多體內器官的纖維化,而雷諾氏現象則常見 於此疾病的早發時期。
雷諾氏現象在臨床上是肢端微血管損傷的表現之一,此種疾病會使得病人在 遇到低溫時引起指尖微血管不正常的收縮。它是經由免疫系統作為媒介所造成血 管內皮細胞損傷,諸如淋巴細胞和單核球細胞的單核細胞則會被吸引到結締組 織,造成纖維母細胞的活化、膠原蛋白的沉積所致,固血管收縮或堵塞或引起組 織缺氧及壞死。 雖然系統性硬化症的初始原因目前仍為未知,其產生多種辨認核內抗原的自 體抗體則為此疾病的一個重要特性。在臨床診斷上,系統性硬化症伴隨著雷諾氏 症病人血液中的抗染色體中心結蛋白及拓樸異構酶自體抗體會明顯增加。而這兩 種自體抗體甚至會造成指尖皮膚的壞死。但這些自體抗體引起血管內皮細胞損傷 的相關機制目前仍不明確。 本篇論文以小牛肺動脈內皮細胞來研究這兩種自體抗體對血管生物學的影 響。我們發現當細胞與抗染色體中心節蛋白培養時,生物能量腺苷三磷酸的製造 會減少,同時,細胞產生的乳酸脫氫酶產生則會受到抗體的作用而增加。由結果 得知,細胞與自己抗體共同培養會改變細胞活性和引起細胞壞死。更進一步,我 們以流式細胞儀偵測 Annexin V/propidium iodide (PI)雙染的螢光訊號,顯示以 抗體處裡過的細胞其細胞凋亡的百分比也會增加。同時我們也用β-半乳糖苷酶染 色法和偵測端粒 DNA 序列的長度發現到受抗體處裡過的細胞會變的更容易產生老 化現象。最重要的是,我們發現當細胞受到抗體的處理過後會引起細胞內 p53 蛋 白的表現。這些結果確認了抗染色體中心節蛋白及拓樸異構酶這兩種自體抗體在 系統性硬化症的細胞毒殺角色。同時,這些自體抗體也會引起內皮細胞中 p53 相 關路徑的細胞凋亡及細胞老化現象。 | zh_TW |
dc.description.abstract | Systemic sclerosis (SSc) is a systemic autoimmune disorder characterized by immune activation, vascular injury, inflammation, and fibrosis in the skin and various internal organs. Raynaud’s phenomenon (RP) is the most common clinical manifestation in the early stage of the disease. RP is a clinical reflection of digital microvascular damage that causing insufficient blood flow in the end of digital and toes in systemic sclerosis (SSc). When the patients suffer from RP, abnormal digital vasoconstriction in response to coldness occurs. It is conceivable that RP is elicited by the immune-mediated vascular endothelial cell injury. Histologically, mononuclear cells such as lymphocytes and monocytes are recruited into the connective tissues, leading to fibroblast activation, collagen accumulation, and tissue hypoxia. Although the initial event leading to the development of SSc is still poorly understood, an important characteristic feature of the disease is the production of a variety of autoantibodies to nuclear antigens. In clinical setting, two unique autoantibodies, anti-centromere (anti-CENP B) and anti-topoisomerase1 (anti-TOPO1), are found elevated in SSc sera concomitantly with RP or even digital skin necrosis. However, the real mechanism of the correlation among autoantibodies and vascular endothelial cell damage remains unclear.
Here, we use the calf pulmonary artery endothelial cells (CPAE) as a model to clarify the affections of these two autoantibodies on vascular biology. We found that the adenosine triphosphate(ATP) production was significantly decreased when cells were incubated with anti-CENP B. Besides, the amount of lactate dehydrogenase (LDH) was increased under treatment of these antibodies. These results suggested that the incubation of autoantibodies with CPAE would destroy cell function and induce cell necrosis. Moreover, the flow cytometrical analysis by annexin V/PI double staining demonstrated that the percentage of apoptotic cell was increased upon antibody treatment. Also, we noticed that the antibody-treated cells tended to become senescence as detected by the senescence-associated β-gal staining and telomere DNA measurement. For elucidating the molecular basis of cell damage, we noted that the antibodies would induce p53 expression in the cells. In conclusion, our data revealed the cytotoxic roles of anti-CENP B and anti-TOPO 1 antibodies on vascular endothelial of patients with SSc through p53 related signaling pathway. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T01:02:42Z (GMT). No. of bitstreams: 1 ntu-100-R97448002-1.pdf: 3282652 bytes, checksum: a1053c719a7b4e4b89d7a3054e8c9b0b (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 誌謝............................................................................................ ii
中文摘要...................................................................................... iii ABSTRACT.................................................................................. v CHAPTER 1 INTRODUCTION............................................................ 3 1.1 Systemic sclerosis........................................................................ 4 1.2 Raynaud’s phenomenon.................................................................8 CHAPTER 2 MATERIALS AND METHODS......................................... 15 2.1 Cell culture.............................................................................. 16 2.2 Monoclonal antibodies and polyclonal antibodies purification.................. 16 2.3 GelCode Blue Stain.................................................................... 18 2.4 Preparation of culture supernatants.................................................. 18 2.5 ELISA.................................................................................... 19 2.6 ATP assay............................................................................... 20 2.7 Cytotoxicity assay...................................................................... 20 2.8 Flow cytometry......................................................................... 21 2.9 Beta-galactosidase staining............................................................ 22 2.10 Telomere PNA FITC for cytometry assay......................................... 22 2.11 Preparation of whole cell extraction................................................ 23 2.12 Western blotting...................................................................... 24 2.13 Statistical analysis..................................................................... 24 CHAPTER 3 RESULTS...................................................................... 25 CHAPTER 4 DISCUSSION................................................................. 32 CHAPTER 5 FIGURES....................................................................... 38 Fig.1 Expression level of vWF upon CPAE cells treated with sera containing autoantibodies........................................................................... 39 Fig.2 Expression level of CD141 upon CPAE cells treated with sera containing autoantibodies........................................................................... 40 Fig.3 Expression level of 6-keto-containing autoantibodies.............................................................. 41 Fig.4 Expression level of ATP upon CPAE cells treated with antibodies.......... 42 Fig.5 Expression level of LDH upon CPAE cells treated with antibodies........... 44 Fig.6 Cells went to apoptosis upon monoclonal antibodies treatment............... 46 Fig.7 Cells went to apoptosis upon purified polyclonal antibodies treatment....... 49 Fig.8 Cells went to apoptosis upon treatment of patients’ sera with non-inactivation containing autoantibodies.............................................................. 52 Fig.9 Cells go to apoptosis upon treatment of patients’ sera with heat-inactivation containing autoantibodies.............................................................. 55 Fig.10 CPAE cells induced senescence upon treatment of antibodies............... 58 Fig.11 CPAE cells induce senescence upon treatment of antibodies................. 65 Fig.12 Antibodies treatments induce p53 expression in CPAE cells................. 67 REFERENCE................................................................................... 70 | |
dc.language.iso | en | |
dc.title | 探討硬皮症相關之自體免疫抗體anti-CENP B和anti-TOPO1對血管內皮細胞之病理作用 | zh_TW |
dc.title | Study on the pathological effects of scleroderma-associated autoantibodies, anti-CENP B and anti-TOPO 1, on vascular endothelial cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 徐立中(Li-Chung Hsu),蔡長祐(Chang-Youh Tsai) | |
dc.subject.keyword | 系統性硬化症,雷諾氏現象,自體抗體,抗染色體中心節蛋白抗體,抗拓樸異構酶,抗體,血管內皮細胞, | zh_TW |
dc.subject.keyword | systemic sclerosis(SSc),Raynaud’s phenomenon(RP),autoantibody,anti-centromere(anti-CENP B),anti-topoisomerase1(anti-TOPO1),vascular endothelial cells, | en |
dc.relation.page | 74 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 3.21 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。